At TauTona, our internally created projects are the direct result of deep clinical expertise. With team members actively practicing medicine, literally in the trenches of healthcare, we understand the challenges that physicians face balancing time and costs while striving for impactful patient results. TauTona identifies, firsthand, the inefficiencies in operating rooms at the point of care. From here, we ideate on technical solutions, determine market size and investment needs, and develop technologies to the commercialization phase. Our dynamic, value-driven approach leverages shared resources across multiple portfolio technologies to minimize overhead and costs. This diligence, coupled with our unparalleled insights, provides an accelerated path to de-risk effective solutions in delivering better care to patients. Better also means faster, simpler and more cost effective for doctors and the healthcare system.
About The TauTona Group
Addressing Unmet Clinical Need With An Entirely New Investment Model
Clinical Insights, De-Risked Development
Smaller Fund, Radical Departure from Today’s Healthcare VCs
Biotech and Health investing has become much more limited, with series A venture capital investments decreasing by over 50% since 2021. With leading healthcare venture capital funds at billions of dollars in size, these funds have no other economic choice but to “swing for the fences” on investments in extremely large markets, abandoning many worthwhile markets with opportunities under $250M in size. Our fund size and approach resemble a lean startup designed to fill the void caused by today’s venture capital financial shifts. We develop technologies for commercialization in medtech, biotech, and regenmed. By investing more modestly, we have the flexibility to evaluate many overlooked market opportunities, both big and “small.” Furthermore, we bypass traditional venture capital completely in our investment approach, eliminating the additional layer of expense that has made medical device investing unsustainable. Our fund dollars go directly to the development of our products.
Our current innovations are in these 3 areas:
- Minimally invasive and laparoscopic surgeries
- Wound care management
- Regenerative medicine
Identify:
- 6 Lenses
- Incubation
- Planning
- Budget to commercialization
Develop:
- Activate Project
- Design/Develop
- Pre-clinical
- Sterilization
- BioComp/Toxicity
- FDA Clearance
- IP
Partner:
- Strategic Investment
- Spin-Out to NewCo
- Exit / Acquisition
